


Supplementary Figure 1: Association between baseline VA and VA at year one and five. In all disease groups, patients in the quartile with lowest baseline VA benefitted more from anti-VEGF injections compared to patients in the quartile with highest baseline VA.



Pathology	Treatment initiation	Re-injections**
AMD	3 monthly injections	series of 3 monthly injections ‡
DME	3-4 monthly injections *	series of 1-3 monthly injections *
RVO	3 monthly injections	series of 3 monthly injections ‡
Myopic CNV	1 injection †	series of 1 - 3 monthly injections *

Supplementary Table 1: Overview of our current PRN treatment protocols.

* based on disease activity / extent of edema

** If disease activity is noted on a follow-up visit, the first injection of the ensuing treatment cycle is given within one to two weeks.

† used to be three initial injections during the first years of data acquisition

‡ TAE allowed in case of minimal disease activity (six and eight week intervals)

Group	AMD (> 50 yrs)	MD (< 50 yrs)	DME	Myopic CNV	RVO
Eyes	1661	41	479	45	351
Patients	1326	38	333	41	334
Mean age	77.8	37.6	64.8	54.4	69.0
Female	840 (63%)	19 (50%)	139 (42%)	26 (63%)	166 (50%)
Mean VA	0.51 ± 0.37	0.50 ± 0.52	0.49 ± 0.38	0.57 ± 0.40	0.54 ± 0.39

Supplementary Table 2: Baseline patient characteristics for all study patients. Mean age is presented in years; mean VA in logMAR.

DME = Diabetic macular edema; AMD = Age-related macular degeneration; MD = Macular disease other than AMD; CNV = choroidal neovascularization; RVO = retinal vein occlusion